Article (Scientific journals)
The estrogen receptor-alpha agonist 16alpha-LE2 inhibits cardiac hypertrophy and improves hemodynamic function in estrogen-deficient spontaneously hypertensive rats.
Pelzer, Theo; Jazbutyte, Virginija; Hu, Kai et al.
2005In Cardiovascular Research, 67 (4), p. 604-12
Peer Reviewed verified by ORBi
 

Files


Full Text
The estrogen receptor-alpha agonist 16alpha-LE2 inhibits cardiac hypertrophy and improves hemodynamic function in estrogen-deficient spontaneously hypertensive rats..pdf
Publisher postprint (360.8 kB)
Request a copy

All documents in ORBilu are protected by a user license.

Send to



Details



Keywords :
Animals; Atrial Natriuretic Factor/metabolism; Cardiomegaly/drug therapy/metabolism/pathology; Estradiol/analogs & derivatives/metabolism/pharmacology/therapeutic use; Estrogen Antagonists/pharmacology; Estrogen Receptor alpha/agonists; Female; Gene Expression/drug effects; Hemodynamics/drug effects; Hypertension/metabolism/pathology; Magnetic Resonance Imaging; Models, Animal; Myocardium/metabolism/pathology; Myosin Heavy Chains/metabolism; Organ Size; Ovariectomy; Papillary Muscles/drug effects; Random Allocation; Rats; Rats, Inbred SHR; Tamoxifen/metabolism/therapeutic use; Ventricular Myosins/metabolism
Abstract :
[en] OBJECTIVE: Cardiac mass increases with age and with declining estradiol serum levels in postmenopausal women. Although the non-selective estrogen receptor-alpha and -beta agonist 17beta-estradiol attenuates cardiac hypertrophy in animal models and in observational studies, it remains unknown whether activation of a specific estrogen receptor subtype (ERalpha or ERbeta) might give similar or divergent results. Therefore, we analyzed myocardial hypertrophy as well as cardiac function and gene expression in ovariectomized, spontaneously hypertensive rats (SHR) treated with the subtype-selective ERalpha agonist 16alpha-LE2 or 17beta-estradiol. METHODS AND RESULTS: Long-term administration of 16alpha-LE2 or 17beta-estradiol did not affect elevated blood pressure, but both agonists efficiently attenuated cardiac hypertrophy and increased cardiac output, left ventricular stroke volume, papillary muscle strip contractility, and cardiac alpha-myosin heavy chain expression. The observed effects of E2 and 16alpha-LE2 were abrogated by the ER antagonist ZM-182780. Improved left ventricular function upon 16alpha-LE2 treatment was also observed in cardiac MRI studies. In contrast to estradiol and 16alpha-LE2, tamoxifen inhibited cardiac hypertrophy but failed to increase alpha-myosin heavy chain expression and cardiac output. CONCLUSIONS: These results support the hypothesis that activation of ERalpha favorably affects cardiac hypertrophy, myocardial contractility, and gene expression in ovariectomized SHR. Further studies are required to determine whether activation ERbeta mediates redundant or divergent effects.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Pelzer, Theo
Jazbutyte, Virginija
Hu, Kai
Segerer, Stephan
Nahrendorf, Matthias
Nordbeck, Peter
Bonz, Andreas W.
Muck, Jenny
Fritzemeier, Karl-Heinrich
Hegele-Hartung, Christa
Ertl, Georg
Neyses, Ludwig ;  University of Luxembourg > Research Office
Language :
English
Title :
The estrogen receptor-alpha agonist 16alpha-LE2 inhibits cardiac hypertrophy and improves hemodynamic function in estrogen-deficient spontaneously hypertensive rats.
Publication date :
2005
Journal title :
Cardiovascular Research
ISSN :
0008-6363
Publisher :
Elsevier, Netherlands
Volume :
67
Issue :
4
Pages :
604-12
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBilu :
since 16 October 2014

Statistics


Number of views
85 (0 by Unilu)
Number of downloads
0 (0 by Unilu)

Scopus citations®
 
76
Scopus citations®
without self-citations
63
OpenCitations
 
68
WoS citations
 
73

Bibliography


Similar publications



Contact ORBilu